# An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

> **NCT02041533** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 541 (actual)

## Conditions studied

- Stage IV or Recurrent Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02041533
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-27
- **Primary completion:** 2016-07-01
- **Final completion:** 2022-05-27
- **Target enrollment:** 541 (ACTUAL)
- **Last updated:** 2023-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02041533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02041533, "An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02041533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*